Spiro George Rombotis
Net Worth

Last updated:

What is Spiro George Rombotis net worth?

The estimated net worth of Mr. Spiro George Rombotis is at least $17,863,240 as of 18 Nov 2021. He owns shares worth $71,645 as insider, has earned $20,875 from insider trading and has received compensation worth at least $17,770,720 in Cyclacel Pharmaceuticals, Inc. and Cyclacel Pharmaceuticals, Inc..

What is the salary of Spiro George Rombotis?

Mr. Spiro George Rombotis salary is $772,640 per year as Pres, Chief Executive Officer & Executive Director in Cyclacel Pharmaceuticals, Inc.. He also receives $772,640 as Pres, Chief Executive Officer & Executive Director in Cyclacel Pharmaceuticals, Inc..

How old is Spiro George Rombotis?

Mr. Spiro George Rombotis is 66 years old, born in 1959.

What stocks does Spiro George Rombotis currently own?

As insider, Mr. Spiro George Rombotis owns shares in 2 companies:

Company Title Shares Price per share Total value
Cyclacel Pharmaceuticals, Inc. (CYCC) Pres, Chief Executive Officer & Executive Director 6,070 $7.53 $45,707
Cyclacel Pharmaceuticals, Inc. (CYCCP) Pres, Chief Executive Officer & Executive Director 4,988 $5.2 $25,938

What does Cyclacel Pharmaceuticals, Inc. do?

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing's disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.

CYCC logo
CYCC
Cyclacel Pharmaceuticals, Inc.
$7.53

What does Cyclacel Pharmaceuticals, Inc. do?

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing's disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.

CYCCP logo
CYCCP
Cyclacel Pharmaceuticals, Inc.
$5.2

Spiro George Rombotis insider trading

Cyclacel Pharmaceuticals, Inc.

Transaction Date Security Shares Price per share Total value Source
Purchase
Common Stock 4,000 $4.5 $18,000

Cyclacel Pharmaceuticals, Inc.

Mr. Spiro George Rombotis has made only one insider trade between 2006-2023, according to the Form 4 filled with the SEC. He purchased 12,140 units of CYCC stock worth $38,727 on 21 Dec 2023.

As of 18 Nov 2021 he still owns at least 6,070 units of CYCC stock.

Transaction Date Security Shares Price per share Total value Source
Purchase
Warrants (right to buy) 12,140 $3.19 $38,727
Purchase
Common Stock 12,140 $3.32 $40,244
Purchase
Common Stock 4,000 $4.5 $18,000
Purchase
Common Stock, $0.001 par value per share 200,000 $3 $600,000
Purchase
Common Stock, $0.001 par value per share 15,902 $0.5 $7,871
Option
Option 75,000 $0.44 $33,000
Option
Common Stock, $0.001 par value per share 75,000 $0.44 $33,000
Purchase
Preferred Convertible Exchangeable Stock 6% 1,200 $3.06 $3,670
Purchase
Common Stock, $0.001 par value per share 24,100 $0.51 $12,171
Purchase
Common Stock, $0.001 par value per share 5,000 $0.59 $2,965
Purchase
Common Stock, $0.001 par value per share 12,000 $0.67 $8,052
Purchase
Preferred Stock, $0.001 par value per share 400 $3.23 $1,291
Purchase
Common Stock, $0.001 par value per share 9,232 $0.73 $6,721
Option
Common Stock, $0.001 par value per share 75,000 $0.44 $33,000
Option
Option 75,000 $0.44 $33,000
Sale
Common Stock, $0.001 par value per share 8,350 $2.5 $20,875
Purchase
Common Stock, par value $0.001 per share 3,000 $0.37 $1,110
Purchase
Common Stock, par value $0.001 per share 900 $0.31 $280
Purchase
Common Stock, par value $0.001 per share 8,000 $0.36 $2,840
Purchase
Common Stock, par value $0.001 per share 17,000 $0.47 $7,922
Purchase
Common Stock, par value $0.001 per share 2,000 $0.5 $1,000
Purchase
Common Stock, par value $0.001 per share 8,900 $1.71 $15,219
Purchase
Common Stock, par value $0.001 per share 100 $1.76 $176
Purchase
Common Stock, par value $0.001 per share 5,000 $2.02 $10,090
Purchase
Common Stock, par value $0.001 per share 5,000 $2.02 $10,090
Purchase
Common Stock, par value $0.001 per share 7,500 $2.3 $17,235
Purchase
Common Stock, par value $0.001 per share 5,000 $2.35 $11,755
Purchase
Common Stock, par value $0.001 per share 5,000 $2.49 $12,430
Purchase
Common Stock, par value $0.001 per share 10,000 $2.64 $26,350
Purchase
Common Stock, par value $0.001 per share 2,600 $2.75 $7,150
Purchase
Common Stock, par value $0.001 per share 3,200 $2.75 $8,800
Purchase
Common Stock, par value $0.001 per share 1,000 $5.47 $5,470
Purchase
Common Stock, par value $0.001 per share 1,400 $5.48 $7,672
Purchase
Common Stock 1,300 $5.56 $7,228
Purchase
Common Stock 100 $6.1 $610
Purchase
Common Stock 100 $5.95 $595
Purchase
Common Stock 100 $5.8 $580
Purchase
Common Stock 300 $5.69 $1,707
Purchase
Common Stock 300 $4.43 $1,329
Purchase
Common Stock 300 $4.43 $1,329
Purchase
Common Stock 100 $7.74 $774

Cyclacel Pharmaceuticals key executives

Cyclacel Pharmaceuticals, Inc. executives and other stock owners filed with the SEC: